Debut Plus

₹917.45

▲ +6.02 +0.66%

As of 10 Sept 2026 · delayed

NSE Listed

Supriya Lifescience Ltd. (SUPRIYA)

Volume: 2,44,416Avg Vol 1W: 4,51,225.4Avg Vol 1M: 3,75,441.7552W Range:₹545.5₹1,085
NSE BSE www.supriyalifescience.com AI Report
Key Ratios
Checked 10h ago
Market Cap₹7,384 Cr
Current Price₹917.45
Previous Close₹911.43
High / Low (52w)₹1,085 / ₹545.5
Volume2,44,416
Avg Vol (1W)4,51,225.4
Avg Vol (1M)3,75,441.75
Stock P/E37.16
Book Value₹148.82
Dividend Yield0%
ROE17.46%
ROA14.62%
Revenue (TTM)₹839 Cr
Revenue Growth—
Profit Margin22.74%
Total Debt—
Shares Outstanding8 Cr
Face Value₹2
EPS (TTM)₹24.69
P/B6.16
Debt / Equity0
50 DMA₹846.31
200 DMA₹765.36
Day change+0.66%
Price Chart
₹917.45▲ 40.16% · 1Y
₹1053₹55358.0L
2025-09-10
2026-09-10

20-day avg volume: 3.8L shares

Pros
  • Healthy return on equity of 17.5%.
  • Company is almost debt-free.
Cons
  • Revenue fell 11% YoY.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹166 Cr₹186 Cr₹184 Cr₹145 Cr₹200 Cr₹206 Cr₹277 Cr₹190 Cr
EBITDA₹62 Cr₹63 Cr₹64 Cr₹48 Cr₹69 Cr₹68 Cr₹93 Cr₹41 Cr
Net Profit₹46 Cr₹47 Cr₹50 Cr₹35 Cr₹50 Cr₹50 Cr₹74 Cr₹24 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹286 Cr₹323 Cr₹396 Cr₹538 Cr₹470 Cr₹581 Cr₹706 Cr₹839 Cr
EBITDA₹67 Cr₹103 Cr₹171 Cr₹211 Cr₹127 Cr₹168 Cr₹250 Cr₹277 Cr
Net Profit₹39 Cr₹73 Cr₹124 Cr₹152 Cr₹90 Cr₹119 Cr₹188 Cr₹209 Cr
EPS5.3910.0216.8918.8611.1614.823.3525.98
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹253 Cr₹336 Cr₹445 Cr₹735 Cr₹820 Cr₹921 Cr₹1,117 Cr₹1,357 Cr
Total Liabilities₹159 Cr₹187 Cr₹177 Cr₹119 Cr₹121 Cr₹106 Cr₹121 Cr₹159 Cr
Equity₹94 Cr₹149 Cr₹269 Cr₹616 Cr₹699 Cr₹815 Cr₹997 Cr₹1,198 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹106 Cr₹110 Cr₹94 Cr₹151 Cr₹224 Cr₹247 Cr
Investing₹-47 Cr₹-60 Cr₹-124 Cr₹-174 Cr₹-152 Cr₹-176 Cr
Financing₹-15 Cr₹150 Cr₹-10 Cr₹-22 Cr₹-8 Cr₹-10 Cr
Free Cash Flow₹106 Cr₹110 Cr₹94 Cr₹151 Cr₹224 Cr₹247 Cr
Shareholding
Promoter 68.3% Institutions 11.49% Public 20.21%
About Supriya Lifescience Ltd.

Pharmaceuticals · Pharmaceuticals - Indian - Bulk Drugs & Formln

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

www.supriyalifescience.com ↗
Efficiency & Working Capital
ROCE23%
Interest Coverage100.2
Dividend Payout—
Debtor Days88 d
Inventory Days64 d
Payable Days44 d
Cash Conversion Cycle107 d
Working Capital Days151 d
Shareholding Details

As of 2026-06-30

Promoter68.3%
FII6.2%
DII5.3%
Institutions11.5%
Public20.2%
Promoter Pledge0%
No. of Shareholders82,082
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%68.3%
FIIs5.3%4.6%5.4%4.9%6%6.5%7.2%6.8%5.5%5.2%5.2%6.2%
DIIs7.2%3.8%5.3%5.5%5.4%4.9%4.3%4.9%5.2%5%5.7%5.3%
Public19.2%23.3%21%21.3%20.2%20.3%20.3%20.1%21%21.5%20.8%20.2%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders92,99195,92987,98089,62185,32889,39491,05191,92887,91285,09981,16182,082
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Satish Waman WaghShareholding of Promoter and Promoter Group67.6%5.44 Cr
Cohesion Mk Best Ideas Sub-trustPublic Shareholding3%24,01,769
Aditya Birla Sun Life Insurance Company LimitedPublic Shareholding2.2%17,61,150
Smita Satish WaghShareholding of Promoter and Promoter Group0.4%3,21,750
Saloni Satish WaghShareholding of Promoter and Promoter Group0.1%1,02,375
Shivani Satish WaghShareholding of Promoter and Promoter Group0.1%1,02,375
Arun Waman WaghShareholding of Promoter and Promoter Group0%110
Satish Waman Wagh Partner Representing SupriyapharmaceuticalsShareholding of Promoter and Promoter Group0%10
Board of Directors
NameDesignationYear
Satish Waman WaghChairman / Executive Director / Managing Director2025
Smita Satish WaghE D & Wholetime Director2025
Saloni Satish WaghE D & Wholetime Director2025
Shivani Satish WaghE D & Wholetime Director2025
Balasaheb G. SawantE D & Wholetime Director2025
Neelam Yashpal AroraIndependent Non Exe. Director2025
Ganapati D YadavIndependent Non Exe. Director2025
Sunil Subhash BhagwatIndependent Non Exe. Director2025
Prachi SatheCompany Sec. & Compli. Officer2025
MANISH ISHWARLAL PANCHALAdditional Independent Director2025
Kothandaraman HariAdditional Independent Director2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2351616
Corporate Actions
TypeDateValueRemark
forthcoming2026-09-04Dividend—
dividend2026-09-04₹1 (50%)Final
forthcoming2026-08-13Board Meetings—
dividend2025-09-04₹1 (50%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202500032234
2025000101
202500031234
Insider / Designated-Person Trades

8 recent disclosure(s)

Shivani Satish WaghAcquisition · 73,125
Saloni Satish WaghDisposal · 73,125
Satish Waman WaghAcquisition · 13,000
Satish Waman WaghAcquisition · 14,000
Satish Waman WaghAcquisition · 2,000
Satish Waman WaghAcquisition · 8,000
Substantial Acquisitions (SAST)

6 disclosure(s)

-26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
Off Market / Inter se transfer26/02/2024 · 73,125
NULL27/12/2023 · 73,125
Company Information
Incorporated2008
ChairmanSatish Waman Wagh
AuditorKakaria & Associates LLP
Investor Email[email protected]
🌐 www.supriyalifescience.com ↗

📍 207/208 Udyog Bhavan, Sonawala Road Goregaon (East), Mumbai, Maharashtra, 400063

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Suprajit Engineering Ltd.Supreme Holdings & Hospitality Ltd.Supreme Engineering Ltd.Supreme Industries Ltd.Supreme Infrastructure India Ltd.Supreme Power Equipment LimitedSuper Tannery Ltd.Suraj Estate Developers LimitedSuraj LimitedSuraksha Diagnostic Ltd.Surana Solar LimitedSurana Telecom and Power Ltd.All “S” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search